GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Liquidia Corp (FRA:LT4) » Definitions » EV-to-EBITDA

Liquidia (FRA:LT4) EV-to-EBITDA : -6.82 (As of Dec. 11, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Liquidia EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Liquidia's enterprise value is €670.96 Mil. Liquidia's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was €-98.41 Mil. Therefore, Liquidia's EV-to-EBITDA for today is -6.82.

The historical rank and industry rank for Liquidia's EV-to-EBITDA or its related term are showing as below:

FRA:LT4' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.41   Med: -6.16   Max: -0.99
Current: -6.61

During the past 8 years, the highest EV-to-EBITDA of Liquidia was -0.99. The lowest was -31.41. And the median was -6.16.

FRA:LT4's EV-to-EBITDA is ranked worse than
100% of 447 companies
in the Biotechnology industry
Industry Median: 9.29 vs FRA:LT4: -6.61

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-12-11), Liquidia's stock price is €10.30. Liquidia's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-1.496. Therefore, Liquidia's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Liquidia EV-to-EBITDA Historical Data

The historical data trend for Liquidia's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Liquidia EV-to-EBITDA Chart

Liquidia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial -2.05 -1.43 -7.56 -9.77 -10.64

Liquidia Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.73 -10.64 -9.91 -7.78 -6.00

Competitive Comparison of Liquidia's EV-to-EBITDA

For the Biotechnology subindustry, Liquidia's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Liquidia's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Liquidia's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Liquidia's EV-to-EBITDA falls into.



Liquidia EV-to-EBITDA Calculation

Liquidia's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=670.962/-98.408
=-6.82

Liquidia's current Enterprise Value is €670.96 Mil.
Liquidia's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-98.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Liquidia  (FRA:LT4) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Liquidia's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=10.30/-1.496
=At Loss

Liquidia's share price for today is €10.30.
Liquidia's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.496.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Liquidia EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Liquidia's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Liquidia Business Description

Traded in Other Exchanges
Address
419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Liquidia Headlines

No Headlines